Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells

Journal of Immunology

Volumn 169, Issue 9, 2002, Pages 4928-4935

  Rubinstein, Mark P ^a   Kadima, Andre N ^a   Salem, Mohamed L ^a   Nguyen, Christophe L ^a   Gillanders, William E ^a   Cole, David J ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 15; INTERLEUKIN 2; PEPTIDE; SERYLISOLEUCYLISOLEUCYLASPARAGINYLPHENYLALANYLGLUTAMYLLYSYLLEUCINE; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DEATH; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNE RESPONSE; LYMPHOCYTE DIFFERENTIATION; MEMORY CELL; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VACCINATION;

EID: 0036838932     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.9.4928     Document Type: Article

References (92)

1. Rosenberg, S. A. 1992. Karnofsky Memorial Lecture: The immunotherapy and gene therapy of cancer. J. Clin. Oncol. 10:180.
2. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321.
3. Rosenberg, S. A., V. T. DeVita, and S. Hellman. 1995. Biologic Therapy of Cancer. Lippincott, Philadelphia, p. xvii.
4. Kovacs, J. A., M. Baseler, R. J. Dewar, S. Vogel, R. T. Davey, Jr., J. Falloon, M. A. Polis, R. E. Walker, R. Stevens, N. P. Salzman, et al. 1995. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection: A preliminary study. N. Engl. J. Med. 332:567.
5. Cheever, M. A., and W. Chen. 1997. Therapy with cultured T cells: Principles revisited, Immunol. Rev. 157:177.
6. Shimizu, K., R. C. Fields, M. Giedlin, and J. J. Mule. 1999. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc. Natl. Acad. Sci. USA 96:2268.
7. Kuroda, K., J. Yagi, K. Imanishi, X. J. Yan, X. Y. Li, W. Fujimaki, H. Kato, T. Miyoshi-Akiyama, Y. Kumazawa, H. Abe, et al. 1996. Implantation of IL-2-containing osmotic pump prolongs the survival of superantigen-reactive T cells expanded in mice injected with bacterial superantigen. J. Immunol. 157:1422.
8. Rosenberg, S. A., J. C. Yang, S. L. Topalian, D. J. Schwartzentruber, J. S. Weber, D. R. Parkinson, C. A. Seipp, J. H. Einhorn, and D. E. White. 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271:907.
9. Baluna, R., and E. S. Vitetta. 1997. Vascular leak syndrome: A side effect of immunotherapy. Immunopharmacology 37:117.
10. Margolin, K. A. 2000. Interleukin-2 in the treatment of renal cancer. Semin. Oncol. 27:194.
11. Schwartzentruber, D. J. 2001. Guidelines for the safe administration of high-dose interleukin-2. J. Immunother. 24:287.
12. Lentsch, A. B., F. N. Miller, and M. J. Edwards. 1999. Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2. Cancer Immunol. Immunother. 47:243.
13. Keilholz, U., G. Stoter, C. J. Punt, C. Scheibenbogen, F. Lejeune, and A. M. Eggermont. 1997. Recombinant interleukin-2-based treatments for advanced melanoma: The experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Cancer J. Sci. Am. 3(Suppl. 1):S22.
14. Dillman, R. O. 1999. What to do with IL-2? Cancer Biother. Radiopharm. 14:423.
15. Cheever, M. A., P. D. Greenberg, C. Irle, J. A. Thompson, D. L. Urdal, D. Y. Mochizuki, C. S, Henney, and S. Gillis. 1984. Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo. J. Immunol. 132:2259.
16. Morgan, D. A., F. W. Ruscetti, and R. Gallo. 1976. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193:1007.
17. Waldmann, T. A. 1986. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 232:727.
18. Rosenberg, S. A. 2000. Principles and Practice of the Biologic Therapy of Cancer. Lippincott-Williams & Wilkins, Philadelphia.
19. Li, X. C., G. Demirci, S. Ferrari-Lacraz, C. Groves, A. Coyle, T. R. Malek, and T. B. Strom. 2001. IL-15 and IL-2: A matter of life and death for T cells in vivo. Nat. Med. 7:114.
20. Waldmann, T. A., S. Dubois, and Y. Tagaya. 2001. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: Implications for immunotherapy. Immunol. 14:105.
21. Van Parijs, L., and A. K. Abbas. 1998. Homeostasis and self-tolerance in the immune system: Turning lymphocytes off. Science 280:243.
22. O'Shea, J. J., A. Ma, and P. Lipsky. 2002. Cytokines and autoimmunity. Nat. Rev. Immunol. 2:37.
23. D'Souza, W. N., K. S. Schluns, D. Masopust, and L. Lefrancois. 2002. Essential role for IL-2 in the regulation of antiviral extralymphoid CD8 T cell responses. J. Immunol. 168:5566.
24. Shrikant, P., and M. F. Mescher. 2002. Opposing effects of IL-2 in tumor immunotherapy: Promoting CD8 T cell growth and inducing apoptosis. J. Immunol. 169:1753.
25. Sadlack, B., H. Merz, H. Schorle, A. Schimpl, A. C. Feller, and I. Horak. 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75:253.
26. Willerford, D. M., J. Chen, J. A. Ferry, L. Davidson, A. Ma, and F. W. Alt. 1995. Interleukin-2 receptor α chain regulates the size and content of the peripheral lymphoid compartment. Immunity 3:521.
27. Lenardo, M. J. 1991. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis. Nature 353:858.
28. + memory T cells by opposing cytokines, Science 288:675.
29. + T cells. Eur. J. Immunol. 31:3248.
30. + memory T cells. J. Immunol. 165:3031.
31. + T cell death. J. Immunol. 163:3131.
32. Refaeli, Y., L. Van Parijs, C. A. London, J. Tschopp, and A. K. Abbas. 1998. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 8:615.
33. Van Parijs, L., Y. Refaeli, J. D. Lord, B. H. Nelson, A. K. Abbas, and D. Baltimore. 1999. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity 11:281.
34. Sussman, J. J., W. L. Wahl, A. E. Chang, and S. Shu. 1995. Unique characteristics associated with systemic adoptive immunotherapy of experimental intracerebral tumors. J. Immunother Emphasis Tumor Immunol. 18:35.
35. Schirrmacher, V., S. Muerkoster, and V. Umansky. 1998. Antagonistic effects of systemic interleukin 2 on immune T cell-mediated graft-versus-leukemia reactivity. Clin. Cancer Res. 4:2635.
36. Kjaergaard, J., L. Peng, P. A. Cohen, J. A. Drazba, A. D. Weinberg, and S. Shu. 2001. Augmentation versus inhibition: Effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J. Immunol. 167:6669.
37. Khoruts, A., A. Mondino, K. A. Pape, S. L. Reiner, and M. K. Jenkins. 1998. A natural immunological adjuvant enhances T cell clonal expansion through a CD28-dependent, interleukin (IL)-2-independent mechanism. J. Exp. Med. 187:225.
38. Bamford. R. N., A. J. Grant, J. D. Burton, C. Peters, G, Kurys, C. K. Goldman, J. Brennan, E. Roessler, and T. A. Waldmann. 1994. The interleukin (IL) 2 receptor β chain is shared by IL-2 and a cytokine provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc. Natl. Acad. Sci. USA 91:4940.
39. Grabstein, K. H., J. Eisenman, K. Shanebeck, C. Rauch, S. Srinivasan, V. Fung, C. Beers, J. Richardson, M. A. Schoenborn, M. Ahdieh, et al. 1994. Cloning of a T cell growth factor that interacts with the β chain of the interleukin-2 receptor. Science 264:965.
40. Burton, J. D., R. N. Bamford, C. Peters, A. J. Grant, G. Kurys, C. K. Goldman, J. Brennan, E. Roessler, and T. A. Waldmann, 1994. A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc. Natl. Acad. Sci. USA 91:4935.
41. + T cells in vivo by IL-15. Immunity 8:591.
42. Estess, P., A. Nandi, M. Mohamadzadeh, and M. H. Siegelman. 1999. Interleukin 15 induces endothelial hyaluronan expression in vitro and promotes activated T cell extravasation through a CD44-dependent pathway in vivo. J. Exp. Med. 190:9.
43. + T cells. J. Exp. Med. 193:219.
44. + T cells following a microbe exposure. J. Immunol. 168:1198.
45. Fefiniger, T. A., and M. A. Caligiuri. 2001. Interleukin 15: Biology and relevance to human disease. Blood 97:14.
46. Waldmann, T., Y. Tagaya, and R. Bamford. 1998. Interleukin-2, interleukin-15, and their receptors. Int. Rev. Immunol. 16:205.
47. Fehniger, T. A., M. A. Cooper, and M. A. Caligiuri. 2002. Interleukin-2 and interleukin-15: Immunotherapy for cancer. Cytokine Growth Factor Rev. 13:169.
48. Sprent, J., and C. D. Surh. 2001. Generation and maintenance of memory T cells. Curr. Opin. Immunol. 13:248.
49. Sprent, J., and C. D. Surh. 2002. T cell memory. Annu. Rev. Immunol. 20:551.
50. Minami, Y., T. Kono, T. Miyazaki, and T. Taniguchi. 1993. The IL-2 receptor complex: Its structure, function, and target genes. Annu. Rev. Immunol. 11:245.
51. Kennedy, M. K., and L. S. Park. 1996. Characterization of interleukin-15 (IL-15) and the IL-15 receptor complex. J Clin. Immunol. 16:134.
52. Waldmann, T. A., and Y. Tagaya. 1999. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu. Rev. Immunol. 17:19.
53. Kennedy, M. K., M. Glaccum, S. N. Brown, E. A. Butz, J. L. Viney, M. Embers, N. Matsuki, K. Charrier, L. Sedger, C. R. Willis, et al. 2000. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 191:771.
54. Lodolce, J. P., D. L. Boone, S. Chai, R. E. Swain, T. Dassopoulos, S. Trettin, and A. Ma. 1998. IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation. Immunity 9:669.
55. + T cells deficient in the IL-15 receptor a-chain. J. Immunol. 168:705.
56. + T cell clones in older mice is controlled by cytokines. J. Immunol. 166:2186.
57. Bulfone-Paus, S., D. Ungureanu, T. Pohl, G. Lindner, R. Paus, R. Ruckert, H. Krause, and U. Kunzendorf. 1997. Interleukin-15 protects from lethal apoptosis in vivo. Nat. Med. 3:1124.
58. + intestinal intraepithelial lymphocytes. J. Immunol. 162:1896.
59. Marks-Konczalik, J., S. Dubois, J. M. Losi, H. Sabzevari, N. Yamada, L. Feigenbaum, T. A. Waldmann, and Y. Tagaya. 2000. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. Proc. Natl. Acad. Sci. USA 97:11445.
60. Carlow, D. A., S. Y. Corbel, M. J. Williams, and H. J. Ziltener. 2001. IL-2, -4, and -15 differentially regulate O-glycan branching and P-selectin ligand formation in activated CD8 T cells. J. Immunol. 167:6841.
61. + T cell responsiveness to antigen. J. Immunol. 161:2141.
62. + T cells rather than promotion of cell death. Proc. Natl. Acad. Sci. USA 99:3001.
63. + T cells. Proc. Natl. Acad. Sci. USA 99:8832.
64. + T cell-mediated immunity in mice infected with a vaccine strain of Toxoplasma gondii. J. Immunol. 163:4503.
65. Zebedee, S. L., D. Barritt, R. Epstein, and W. C. Raschke. 1991. Analysis of Ly5 chromosome 1 position using allelic differences and recombinant inbred mice. Eur. J. Immunogenet. 18:155.
66. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, and F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76:17.
67. Shevach, E. M., J. D. Stobo, and I. Green. 1972. Immunoglobulin and theta-bearing murine leukemias and lymphomas. J. Immunol. 108:1146.
68. Moore, M. W., F. R. Carbone, and M. J. Bevan. 1988. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54:777.
69. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693.
70. Fields, R. C., J. J. Osterholzer, J. A. Fuller, E. K. Thomas, P. J. Geraghty, and J. J. Mule. 1998. Comparative analysis of murine dendritic cells derived from spleen and bone marrow. J. Immunother. 21:323.
71. Kim, S. K., D. S. Reed, S. Olson, M. J. Schnell, J. K. Rose, P. A. Morton, and L. Lefrancois. 1998. Generation of mucosal cytotoxic T cells against soluble protein by tissue-specific environmental and costimulatory signals. Proc. Natl. Acad. Sci. USA 95:10814.
72. + T cell ignorance and induction of anti-tumor immunity by peptide-pulsed APC. J. Immunol. 165:6731.
73. Nguyen, C. L., J. T. Bui, M. Demcheva. J. N. Voumakis, D. J. Cole, and W. E. Gillanders. 2001. Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response. J. Immunother. 24:420.
74. + T cells. J. Immunol. Methods 238:107.
75. Adams, J. M., and S. Cory. 1998. The Bcl-2 protein family: arbiters of cell survival. Science 281:1322.
76. + T cells. J. Immunol. 164:3950.
77. Mor, F., and I. R. Cohen. 1996. IL-2 rescues antigen-specific T cells from radiation or dexamethasone-induced apoptosis: correlation with induction of Bcl-2. J. Immunol. 156:515.
78. Adachi, M., T. Torigoe, S. Takayama, and K. Imai. 1998. BAG-1 and Bcl-2 in IL-2 signaling. Leuk. Lymphoma 30:483.
79. S) gene expression. Eur. J. Immunol. 26:294.
80. Mitchell, T., J. Kappler, and P. Marrack. 1999. Bystander virus infection prolongs activated T cell survival. J. Immunol. 162:4527.
81. + T cells secreting Th1 or Th2 cytokines. Immunol 2:271.
82. + T cell subpopulations in established pulmonary metastases. J. Immunol. 162:6671.
83. Kourilsky, P., and P. Truffa-Bachi. 2001. Cytokine fields and the polarization of the immune response. Trends Immunol 22:502.
84. Lenardo, M., K. M. Chan, F. Hornung, H. McFarland, R. Siegel, J. Wang, and L. Zheng. 1999. Mature T lymphocyte apoptosis: Immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol. 17:221.
85. Kim, S. K., K. S. Schluns, and L. Lefrancois. 1999. Induction and visualization of mucosal memory CD8 T cells following systemic virus infection. J. Immunol. 163:4125.
86. Lefrancois, L., J. D. Altman, K. Williams, and S. Olson. 2000. Soluble antigen and CD40 triggering are sufficient to induce primary and memory cytotoxic T cells. J. Immunol. 164:725.
87. Lauvau, G., S. Vijh, P. Kong, T. Homg, K. Kerksiek, N. Serbina, R. A. Tuma, and E. G. Pamer. 2001. Priming of memory but not effector CD8 T cells by a killed bacterial vaccine. Science 294:1735.
88. Katsanis, E., Z. Xu, A. Panoskaltsis-Mortari, D. J. Weisdorf, M. B. Widmer. and B. R. Blazar. 1996. IL-15 administration following syngeneic bone marrow transplantation prolongs survival of lymphoma bearing mice. Transplantation 62:872.
89. Kobayashi, H., J. A. Carrasquillo, C. H. Paik, T. A. Waldmann, and Y. Tagaya, 2000. Differences of biodistribution, pharmacokinetics and tumor targeting between interleukins 2 and 15. Cancer Res. 60:3577.
90. Shanafelt, A. B., Y. Lin, M. C. Shanafelt, C. P. Forte, N. Dubois-Stringfellow, C. Carter, J. A. Gibbons, S. L. Cheng, K. A. Delaria, R. Fleischer, et al. 2000. A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nat. Biotechnol. 18:1197.
91. Barouch, D. H., S. Santra, T. D. Steenbeke, X. X. Zheng, H. C. Perry, M. E. Davies, D. C. Freed, A. Craiu, T. B. Strom, J. W. Shiver, et al. 1998. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J. Immunol. 161:1875.
92. Rizzo, L. V., N. E. Miller-Rivero, C. C. Chan, B. Wiggert, R. B. Nussenblatt, and R. R. Caspi. 1994. Interleukin-2 treatment potentiates induction of oral tolerance in a murine model of autoimmunity. J. Clin. Invest. 94:1668.